Media Center

All news News

  • 18 September 2018

    Positive PEACHTREE Data to be Highlighted at EURETINA 2018

    Positive PEACHTREE Data to be Highlighted at EURETINA 2018

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Ron Neumann , MD, Uveitis Specialist at  Maccabi Health Services ,  Tel Aviv, Israel  and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming  European Society of Retina Specialists (EURETINA) Congress  2018 in  Vienna, Austria.

  • 13 September 2018

    Data From Clearside Biomedicals Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

    Data From Clearside Biomedicals Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Rahul N. Khurana , MD, an investigator for PEACHTREE, Partner at  Northern California Retina Vitreous Associates , and Clinical Associate Professor in Ophthalmology at  UCSF Medical Center , during a scientific session on Inflammation at the  Retina Society  51st Annual Scientific Meeting in  San Francisco , California. 

  • 12 September 2018

    Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

    Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position of Vice President, Discovery. 

  • 12 September 2018

    Epic Sciences Announces Completion of $52 Million Series E Financing

    Epic Sciences Announces Completion of $52 Million Series E Financing

    Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing.  

  • 11 September 2018

    Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

    Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Leslie Zacks  as General Counsel and Chief Compliance Officer.

  • 06 September 2018

    Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality

    Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality

    Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President, Quality.​

  • 05 September 2018

    Marinus Appoints Scott Braunstein, MD to its Board of Directors

    Marinus Appoints Scott Braunstein, MD to its Board of Directors

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Dr.  Scott Braunstein  to its Board of Directors. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points.

  • 04 September 2018

    Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer

    Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer

    Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer. In this new role, Atkinson will be responsible for the development of Epic’s global commercial strategy by identifying new strategic business opportunities and deepening its existing strategic partnerships.   

  • 29 August 2018

    Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora, for the Prevention of Chlamydia

    Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora, for the Prevention of Chlamydia

    Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, believes that new data recently released by the Centers for Disease Control and Prevention (CDC) on the increasing rates of sexually transmitted diseases (STDs) in the United States support the continued need for and clinical development of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhea in women.

  • 08 August 2018

    Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended  June 30, 2018  and provided an update on its development programs.

All publications Media about us